Articles tagged "Antibodies"

2019 American Transplant Congress
NK Cell Quantification by Paraffin Immunohistochemistry is Not Predictive of Graft Outcome in 1-Year Surveillance Biopsies
J. Barnes¹, F. Suliman², A. Shammout¹, E. A. Farkash¹
¹Pathology, Michigan Medicine, Ann Arbor, MI, ²Nephrology, Michigan Medicine, Ann Arbor, MI
*Purpose: Molecular and animal studies have identified NK cells as important mediators and markers of antibody mediated rejection. Using three color immunohistochemistry for CD16, T-bet,…
2019 American Transplant Congress
Anti-ebv Antibody (ebv-ab) And Ebv-specific Cytotoxic T Cell (ebv-tc) Positivity Are Essential To Control Viremia In Seronegative (sero[-]) Pediatric Kidney Transplant Recipients (ped Ktx Pts).
B. Shin, H. Pizzo, D. Puliyanda, A. Petrosyan, D. Lovato, S. C. Jordan, M. Toyoda
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: EBV infection represents a significant morbidity factor in KTx Pts, especially EBV sero(-) Ped as infections tend to be more severe and recurrent, increasing…
2019 American Transplant Congress
Donor-Derived Cell-Free DNA (dd-cfDNA) Course after Rejection in Pediatric Kidney Transplant Recipients
R. D. Swinford¹, A. M. De Golovine¹, C. Bell¹, A. Pai¹, A. R. Edwards¹, S. Connor², J. S. Bynon¹
¹Pediatrics, UTHealth, McGovern Medical School, University of Texas at Houston, Houston, TX, ²Transplantation, Memorial Hermann Hospital, Houston, TX
*Purpose: Accurate identification of successful treatment for rejection (R) without repeat kidney biopsy (KB) in kidney transplantation is an unmet need. The few existing biomarkers…
2019 American Transplant Congress
Clazakizumab as an Agent to Reduce Donor Specific HLA Antibodies and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation
S. C. Jordan¹, N. Ammerman¹, M. Toyoda², E. Huang¹, C. C. Nast³, A. Peng¹, S. Sethi¹, R. Najjar¹, I. Kim¹, K. Lim¹, J. Choi¹, A. Vo¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Lab, Cedars-Sinai Medical Ctr, Los Angeles, CA, ³Department of Pathology, Cedars-Sinai Medical Ctr, Los Angeles, CA
*Purpose: Highly sensitized (HS) patients are at an increased risk for chronic antibody mediated rejection (cABMR) and graft loss due to persistent, deleterious DSA production.…
2019 American Transplant Congress
Multiple Non-HLA Antibodies Are Significantly Increased in Chronic Active Antibody Mediated Rejection
K. Sablik¹, E. Kamburova², D. Roelen³, H. Otten², M. Betjes¹
¹Erasmus MC, Rotterdam, Netherlands, ²University Medical Center Utrecht, Utrecht, Netherlands, ³University Medical Center Leiden, Leiden, Netherlands
*Purpose: Chronic-active antibody mediated rejection (c-aABMR) is characterized by continuous inflammation at the level of the microvascular endothelium. Although donor-specific anti-HLA antibodies play an important…
2019 American Transplant Congress
Circulating De Novo Donor Specific Antibodies and Carotid Intima-Media Thickness in Pediatric Kidney Transplant Recipients
K. Sgambat¹, S. Clauss², A. Moudgil¹
¹Nephrology, Children's National, Washington DC, DC, ²Cardiology, Children's National, Washington DC, DC
*Purpose: Emerging evidence suggests that circulating de novo donor specific anti-HLA antibodies (dnDSA) may be associated with increased risk of accelerated systemic arteriosclerosis and major…
2019 American Transplant Congress
CD4 T Cell is Essential in an Innate-Immune Driven Ischemia-Reperfusion Injury in Mouse and Human
S. Kageyama¹, K. Kadono¹, H. Hirao¹, K. Nakamura¹, T. Ito², K. J. Dery¹, D. Oncel¹, R. A. Sosa³, E. F. Reed³, F. M. Kaldas², R. W. Busuttil², J. W. Kupiec-Weglinski¹, Y. Zhai¹
¹Surgery, Dumont-UCLA Transplant Center, Los Angeles, CA, ²Surgery, Ronald Reagan UCLA Medical Center, Los Angeles, CA, ³Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA
*Purpose: Although CD4 T cells are critical in the mechanism of allograft rejection, little is known about their role in the innate immune-driven ischemia-reperfusion injury…
2019 American Transplant Congress
Long Term Outcomes Using Tocilizumab For The Treatment Of Chronic Antibody Mediated Rejection
J. Choi¹, E. Huang¹, O. Aubert², A. Vo¹, A. Peng¹, R. Najjar¹, S. Sethi¹, N. Ammerman¹, K. Lim¹, D. Puliyanda¹, A. Loupy², S. Jordan¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, ²Paris Translational Center for Organ Transplantation, Paris, France
*Purpose: Limited options exist for the treatment of kidney allograft rejection and preservation of allograft function. We reported our experience with anti-IL-6R (tocilizumab, TCZ) as…
2019 American Transplant Congress
Significance of Histopathologic Features for Predicting Progression in Patients with Transplant Glomerulopathy
X. Li, J. Chen, D. Cheng, R. Wang, W. Wang, M. Zhang, F. Xu, J. Wen, Z. Tang
National Clinical Research Center of Kidney Diseases, Nanjing, China
*Purpose: Transplant glomerulopathy (TG) represents a major cause of long-term allograft failure and is the leading cause of overall post-transplant proteinuria. We aimed to determine…
2019 American Transplant Congress
Anti-cmv Antibody (cmv-ab) And Cmv-specific Cytotoxic T Cell (cmv-tc) Positivity Are Essential To Control Severe Viremia In Seronegative (sero[-]) Pediatric Kidney Transplant Recipients (ped Ktx Pts).
B. Shin, H. Pizzo, D. Puliyanda, A. Petrosyan, D. Lovato, S. C. Jordan, M. Toyoda
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: CMV infection represents a significant morbidity factor in KTx Pts, especially CMV sero(-) Ped Pts as infections tend to be more severe and recurrent.…